



Immunonutrition: Biomedical Basis for Disease Management 2.0

Guest Editor:

Dr. Jose Laparra Llopis

Madrid Institute for Advanced
Studies in Food (IMDEA Food),
Madrid, Spain

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editor

Knowledge about the impact of immunonutritional agonists on citizens' health can offer a way to reduce the risk of suffering chronic diseases and even offer a therapeutic potential on these. Innate and adaptive immune effectors operate sequentially and in distinct ways during normal development to prevent alterations in tissue metabolic homeostasis as well as to establish steady-state commensalism. Those are key to correct the distinctive stamp in alterations to the homeostasis of nutrients, leading to immunometabolic-based diseases with a strong impact on future morbidity rates and a reduction in the life expectancy of the population (i.e., non-alcoholic fatty liver disease, metabolic syndrome, cancer). There is evidence of the relevance of perinatal nutrition to developmental programming of innate immune effectors, worsening or improving their contribution to the risk of disease development. Identification and development of immunonutritional agonists, as well as definition of their biomedical action based on life sciences, can greatly accelerate our progress toward precision medicine in health promotion.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)